Daniel J. Tenney

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy #

Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick et al. · Hepatology · 2009 · 816 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B

Ting‐Tsung Chang, Ching‐Lung Lai, Seung Kew Yoon et al. · Hepatology · 2010 · 586 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Daniel J. Tenney, Steven M. LeVine, R.E. Rose et al. · Antimicrobial Agents and Chemotherapy · 2004 · 538 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Entecavir resistance is rare in nucleoside naïve patients with hepatitis B

Richard J. Colonno, Ronald E. Rose, Carl J. Baldick et al. · Hepatology · 2006 · 348 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions Present

Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick et al. · Antimicrobial Agents and Chemotherapy · 2006 · 239 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17